Anti-PD-1 and CTLA-4 Combination Therapy for Chemoresistant NSCLC

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Non-small cell lung cancer (NSCLC) is relatively insensitive to chemotherapy, and existing immunotherapies using PD-1 and CTLA-4 inhibitors have not been extensively tested in combination for efficacy in lung cancer types beyond melanoma.

Innovation Solution

Administering a combination of anti-PD-1 and anti-CTLA-4 antibodies, such as nivolumab and ipilimumab, to patients with NSCLC, either sequentially or concurrently, in specific dosing regimens to enhance antitumor activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If chemotherapy is used to treat non-small cell lung cancer, then treatment is administered, but the cancer is relatively insensitive to chemotherapy

Engineering Contradiction:

Improvetreatment efficacyVSAvoidchemoresistance

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent changes the treatment parameter from chemotherapy to immunotherapy by administering anti-PD-1 and anti-CTLA-4 antibodies, thereby overcoming the chemoresistance of NSCLC and achieving durable clinical responses in patients who did not respond to conventional chemotherapy

Inventive Principle:

Principle #35Parameter changes

2Reliability

If PD-1 inhibitor alone is administered, then treatment is provided, but antitumor activity is limited

Engineering Contradiction:

Improveantitumor activityVSAvoidtreatment effectiveness

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent combines two different immunotherapeutic agents (anti-PD-1 antibody and anti-CTLA-4 antibody) into a single treatment regimen, thereby synergistically enhancing antitumor activity and achieving durable clinical responses that are superior to either agent alone

Inventive Principle:

Principle #5Merging (Combining)

3Reliability

If combination immunotherapy is administered, then treatment outcomes improve, but treatment complexity increases

Engineering Contradiction:

Improveclinical response durabilityVSAvoidtreatment regimen complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent establishes predetermined dosing regimens and administration schedules for the combination therapy, with specific dosing intervals and sequences that simplify the complex treatment protocol while maintaining the durable clinical responses achieved through combination immunotherapy

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentUS20260092114A1Treatment of lung cancer using a combination of an Anti-PD-1 antibody and another Anti-cancer agent

Publication Date: 2026.04.02 BRISTOL MYERS SQUIBB CO

AI summary

This disclosure provides a method for treating a subject afflicted with a lung cancer, which method comprises administering to the subject therapeutically effective amounts of: (a) an anti-cancer agent which is an antibody or an antigen-binding portion thereof that specifically binds to a Programmed Death-1 (PD-1) receptor and inhibits PD-1 activity which can be administered by infusion for less than 60 minutes; and, optionally, (b) another anti-cancer agent which is administered by infusion for less than 90 minutes. The other anti-cancer agent can be an anti-Cytotoxic T-Lymphocyte Antigen-4 (CTLA-4) antibody.